Search by CAS No , Chemical Name or Molecular Formula
Long Term Storage
Off-White to Pale Beige Solid
"Bupropion is a medication primarily used as an antidepressant and smoking cessation aid. It is marketed as Wellbutrin and Zyban among other trade names. It is one of the most frequently prescribed antidepressants in the United States and Canada, although in many countries this is an off-label use. It is an effective antidepressant on its own, but is also popular as an add-on medication in cases of incomplete response to first-line SSRI antidepressants. Bupropion is taken in tablet form and is available only by prescription in most countries.
The most important side effect is an increase in risk for epileptic seizures, which caused the drug to be withdrawn from the market for some time and then caused the recommended dosage to be reduced. In comparison to many other antidepressants, it does not cause as much weight gain, sexual dysfunction, or sleepiness. Bupropion acts as an norepinephrine-dopamine reuptake inhibitor (NDRI). It is an atypical antidepressant, different from most commonly prescribed antidepressants such as selective serotonin reuptake inhibitors (SSRIs).
Bupropion is known to affect several different biological targets. It often is described as a norepinephrine-dopamine reuptake inhibitor (NDRI), and is also a nicotinic antagonist. However, bupropion does not appear to have significant dopaminergic actions in humans under normal clinical circumstances. Chemically, bupropion belongs to the class of aminoketones and is similar in structure to stimulants such as cathinone and amfepramone, and to phenethylamines in general.
Bupropion was first made by Nariman Mehta and patented by Burroughs Wellcome in 1969, which later became part of what is now GlaxoSmithKline. It was first approved for medical use in the United States in 1989. It was originally called by the generic name amfebutamone, before being renamed in 2000.",""
Labeled Metabolite of Bupropion, intended for use as an internal standard for the quantification of Bupropion by GC- or LC-mass spectrometry.
Bupropion Morpholinol D6;2-((1-hydroxy-2-methylpropan d6-2-yl)amino)-1-phenylpropan-1-one;
Soroko, F., et al.: J. Pharm. Pharmcol., 29, 769 (1977), Tcker, W.E., J.clin. Pschiatry, 44, 60 (1983), Hsyu, P-H., et al.: J.clin. Pharmcol., 37, 737 (1997), West, R., et al.: Expert Opin. Pharmcother., 4, 533 (2003),
We normally respond within 8 hours.
This page contains information about Hydroxy Bupropion D6 Cas # 1216893-18-3 and its Stable Isotopes.
Hydroxy Bupropion D6 Hydroxy Bupropion D6 Worldwide Suppliers of Hydroxy Bupropion D6 https://www.clearsynth.com/en/CSO02798.html Stable Isotopes Clearsynth 1216893-18-3
Regular price: $800 In stock
Product rating: 9 Hydroxy Bupropion D6 based on 20 ratings
Keywords: Stable Isotopes Bupropion Morpholinol D6;2-((1-hydroxy-2-methylpropan d6-2-yl)amino)-1-phenylpropan-1-one; CS-O-02798 Hydroxy Bupropion D6 Bupropion 1216893-18-3 261.78 C13H12DClNO2
Internal standard, Internal standard Bupropion, HPLC-MS method validation, HPLC-MS method validation Bupropion, LC-MS-MS method validation, LC-MS-MS method validation Bupropion, Deuterated internal standard, Deuterated internal standard Bupropion, Deuterated Bupropion, Deuterium labeled Bupropion, Quantitative bioanalytical methods, Quantitative bioanalytical methods Bupropion, Blood samples Bupropion, Blood concentrations, Heavy drugs, Analysis, Analysis Bupropion, Clinical diagnostic, Clinical diagnostic Bupropion, Dosing Bupropion, Analytical method development, Internal standard method.
CLEARSYNTH CANADA INC.
2395 Speakman Drive,
Lab: 1001, Mississauga, ON,
Canada L5K 1B3
T : +1-289-729-0060
CLEARSYNTH RESEARCH CENTRE
Plot No. 177, IDA, Mallapur,
T : +91-40-27155481
CLEARSYNTH LABS LTD
17, Lotus Business Park,
Andheri (W), Mumbai - 400053
T : +91-22-45045945